Adaptimmune Therapeutics Plc

$0.24
(as of Apr 17, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Adaptimmune Therapeutics Plc

Stock Price
$0.24
Ticker Symbol
ADAP
Exchange
NASDAQ

Industry Information for Adaptimmune Therapeutics Plc

Sector
Healthcare
Industry
Biotechnology

Company Description for Adaptimmune Therapeutics Plc

Website
https://www.adaptimmune.com
Country
USA
Full Time Employees
506

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Fundamentals for Adaptimmune Therapeutics Plc

Market Capitalization
$61,272,660
EBITDA
$-41,184,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.30
Earnings per Share Estimate Next Year
Profit Margin
-39.78%
Shares Outstanding
257,232,000
Percent Owned by Insiders
0.31%
Percent Owned by Institutions
49.56%
52-Week High
52-Week Low

Technical Indicators for Adaptimmune Therapeutics Plc

50-Day Moving Average
200-Day Moving Average
RSI
37.8
ATR
0.04

Analyst Ratings for Adaptimmune Therapeutics Plc

Strong Buy
4
Buy
2
Hold
2
Sell
1
Strong Sell
0

News About Adaptimmune Therapeutics Plc

Aug 12, 2024, 8:47 AM EST
By Michael Kim See more.
Jul 3, 2024, 11:11 AM EST
For most of the year, biotech has been one of the most explosive sectors on the market. See more.
May 30, 2024, 4:01 PM EST
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications See more.
May 30, 2024, 4:01 PM EST
Galapagos NV See more.